About the Company
We do not have any company description for HilleVax, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on HilleVax, Inc.
HilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional ...
Every investor in HilleVax, Inc. (NASDAQ:HLVX) should be aware of the most powerful shareholder groups. The group holding the most number of shares in the company, around 51% to be precise, is ...
HilleVax, Inc. (HLVX) Latest Stock News & Headlines - Yahoo Finance
Get the latest HilleVax, Inc. (HLVX) stock news and headlines to help you in your trading and investing decisions.
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
(“HilleVax” or “the Company”) (NASDAQ: HLVX) and XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA) announced today they have entered into a definitive merger agreement (the “Merger Agreement”), ...
HilleVax, Inc. (HLVX) - Yahoo Finance
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is ...
What Makes HilleVax (HLVX) a New Buy Stock - Nasdaq
HilleVax, Inc. (HLVX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...
HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade
HilleVax, Inc. (HLVX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...
HilleVax: Mid-2024 Data Is Crucial Inflection Point For Continued ...
Summary HilleVax, Inc. top line results from the phase 2/3 NEST-IN1 study, using HIL-214 for the prevention of Norovirus-related gastroenteritis, expected mid-2024.
HilleVax, Inc. (HLVX) latest press releases and corporate news ...
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is ...
HilleVax, Inc: Analyst Maintains Hold Rating Amid Vaccine Trial Setback ...
Matthew Caufield has given his Hold rating due to a combination of factors influencing HilleVax, Inc’s current situation. The recent failure of the Phase 2B NEST-IN1 trial for the HIL-214 ...
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
The Ademi Firm is investigating HilleVax (NASDAQ: HLVX) for possible breaches of fiduciary duty and other violations of law in its transaction with XOMA Royalty Corporation.
HilleVax, Inc.: HilleVax Enters into a Definitive Agreement to be ...
Aktien»Nachrichten»XOMA ROYALTY AKTIE»HilleVax, Inc.: HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right ...
HilleVax, Inc. (HLVX) latest stock news and headlines – Yahoo Finance
HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress $245.0 million of cash, cash equivalents and marketable securities as of June 30, 2024 The company is ...
Similar Companies
Loading the latest forecasts...